How to Treat Low Immunoglobulin E (IgE) Levels

There is no approved drug or therapy that directly raises immunoglobulin E levels. Low IgE is not treated the way you might treat low iron or low vitamin D, with a supplement that tops off what’s missing. Instead, clinicians treat the underlying condition that caused IgE to drop and manage the downstream consequences, which can include recurrent infections, autoimmune problems, and a heightened cancer risk. The approach depends heavily on what the workup reveals, because very low IgE often signals a broader immune deficiency rather than a standalone problem.

What Counts as Low IgE

IgE circulates at far lower concentrations than other antibodies. While IgG, the most abundant immunoglobulin, typically runs in the range of several hundred to over a thousand milligrams per deciliter, IgE is measured in international units per milliliter and normally sits somewhere between a few IU/mL and a couple hundred. Clinicians generally consider serum IgE below 2.5 IU/mL to be low, and “selective IgE deficiency” refers to patients whose IgE is reduced while their IgA, IgG, and IgM levels remain normal.¹ Many labs report IgE as “undetectable” when it falls below their lower limit, which varies by assay but typically sits around 2 IU/mL.

A result that reads “undetectable” does not always mean something is wrong. Some healthy people naturally produce very little IgE. But in clinical practice, an undetectable reading is treated as a red flag worth investigating, particularly when a patient has a history of repeated infections or other immune-related symptoms.

Why IgE Is Worth Caring About

Most people associate IgE with allergies, and for good reason: it’s the antibody that drives hay fever, hives, and anaphylaxis. But allergy is not its original job. IgE evolved primarily to fight parasites, especially helminths (worms), and more recent research has identified roles in defense against certain venoms, toxins, and microbial pathogens, as well as in immune surveillance against abnormal cells.² That immune surveillance function is part of why very low IgE has been linked to cancer risk, a connection covered later in this article.

What Causes IgE to Be Low

A low IgE reading on its own is a clue, not a diagnosis. The critical question is whether it’s an isolated quirk or the tip of a larger immune deficiency. In one study of patients referred to an immunodeficiency clinic, 93% of those with very low IgE turned out to have either a primary or secondary antibody deficiency.³ That’s a striking number, and it’s the main reason clinicians take a low IgE result seriously.

Common Variable Immunodeficiency

The condition most strongly linked to low IgE is common variable immunodeficiency, or CVID, the most frequently diagnosed symptomatic primary immunodeficiency in adults. About three-quarters of CVID patients have undetectable IgE, and a very high IgE is essentially unheard of in this population.⁴ In fact, researchers have proposed using undetectable IgE as a screening marker to help distinguish CVID from secondary causes of low immunoglobulins, such as medication side effects. When IgE is above 2 IU/mL, secondary causes of low antibodies become much more likely.

Within the CVID population, having undetectable IgE carries its own prognostic weight. Patients with undetectable IgE tend to have lower levels of IgG, IgM, and IgA as well, along with reduced numbers of certain immune cells, including CD4+ T cells and memory B cells. These patients also face a higher frequency of autoimmune blood cell destruction (autoimmune cytopenias) and lymphoma compared to CVID patients whose IgE is merely low but still detectable.⁵ Separately, one study found that low IgE in CVID patients with autoimmune overlap was an independent risk factor for developing autoimmune disease, with roughly a threefold increase in odds.⁶

Other Primary Immunodeficiencies

CVID is not the only primary immunodeficiency where IgE drops. Data from the U.S. Immunodeficiency Network registry found that IgE deficiency was common in hyper-IgM syndrome (about 39% of patients), X-linked agammaglobulinemia (about 38%), and CVID (about 34%).⁷ In X-linked agammaglobulinemia, B cells fail to develop properly, so all immunoglobulin classes tend to be severely reduced. In hyper-IgM syndrome, the B cells can’t perform the molecular switch that produces IgE (or IgG or IgA), leaving IgM as essentially the only antibody class produced in quantity.

Secondary Causes

Not every case of low IgE traces to a genetic immune defect. Medications that suppress the immune system, including certain chemotherapy agents and immunosuppressants, can drive IgE down as a side effect. Some chronic infections and malignancies can also suppress antibody production more broadly. The clinical challenge is separating these reversible causes from primary immunodeficiencies, because the treatment path differs considerably.

Health Risks Tied to Low IgE

Low IgE matters clinically because of the problems that cluster around it. These fall into three broad categories.

Recurrent Infections

The most immediate concern is respiratory tract infections. An early case series describing familial IgE deficiency documented chronic sinopulmonary infections in affected family members, with the two oldest showing progressive loss of lung function and signs of pulmonary fibrosis, possibly driven by years of chronic infection.⁸ While IgE itself is not the primary antibody fighting bacteria in the lungs (that’s mostly IgG and IgA), low IgE is frequently a companion to broader antibody deficiency, and the infection burden comes from the overall immunoglobulin shortfall rather than the IgE drop alone.

Autoimmune Disease

Autoimmune conditions show up with striking regularity in people with very low IgE. In a study evaluating patients whose serum IgE was very low, about 15% had an autoimmune disease.⁹ When the underlying diagnosis is CVID, the autoimmune link is even stronger, as noted earlier with the threefold risk increase. The precise mechanism connecting low IgE to autoimmunity isn’t fully worked out, but it likely reflects the same B cell dysfunction that reduces IgE production: the immune system isn’t just underperforming; it’s dysregulated, prone to attacking self as well as failing to fight pathogens effectively.

Malignancy

The association between low IgE and cancer is one of the more surprising findings in this space. In the same cohort study of very low IgE patients, about a quarter had a malignancy.⁹ The cancer connection appears strongest for blood cancers. A large study found that higher IgE levels were associated with lower risk of chronic lymphocytic leukemia (CLL) and multiple myeloma, suggesting that IgE may play some protective role.¹⁰ A separate large retrospective cohort confirmed this from the opposite direction: people with serum IgE below 25 IU/mL had roughly double the hazard of developing CLL compared to those with higher levels.¹¹

One proposed explanation draws on what researchers call “AllergoOncology,” the idea that IgE cooperates with specific receptors on immune cells to identify and destroy abnormal cells. Patients with ultra-low IgE who also have negative allergy skin tests, meaning they lack both circulating and tissue-bound IgE, appear to be at the highest risk for malignancy. In contrast, IgE-deficient patients who still show positive skin tests (indicating some IgE remains bound to cells even when serum levels are undetectable) have lower cancer rates.¹² This distinction is clinically useful and suggests that a simple blood IgE level doesn’t tell the whole story about cancer surveillance capacity.

The Diagnostic Workup

When a clinician discovers low or undetectable IgE, the first step is not treatment but investigation. A typical workup includes measuring the other immunoglobulin classes (IgG, including subclasses, IgA, and IgM) to determine whether the deficiency is isolated to IgE or part of a broader pattern. In immunodeficiency clinic referrals, low IgE correlated strongly with low IgG and IgA, while IgM was often spared.³ The IgG subclass profile can also provide clues: IgG2 and IgG4 tend to track most closely with IgE in immunodeficiency patients.

Beyond antibody levels, the workup usually includes lymphocyte subset analysis (counting different types of T and B cells), vaccine response testing (checking whether the patient can mount a normal antibody response to immunization), and a thorough infection history. The goal is to determine whether the patient has CVID, another primary immunodeficiency, or a secondary cause that might be reversible.

For patients with isolated low IgE and no symptoms, the evidence doesn’t clearly support aggressive intervention. But most experts recommend periodic monitoring, particularly for infections and signs of autoimmune or malignant disease, given the associations described above.

Immunoglobulin Replacement Therapy

For patients whose low IgE is part of a broader antibody deficiency, particularly CVID, immunoglobulin replacement therapy (IRT) is the cornerstone of treatment. IRT provides pooled IgG from thousands of donors, delivered either intravenously (IVIG, typically every three to four weeks) or subcutaneously (SCIG, often weekly or biweekly). It significantly reduces both the frequency and severity of infections in patients with meaningful antibody deficiencies.¹³

It’s worth being clear about what IRT does and does not do. It replaces IgG, not IgE. No commercial immunoglobulin product is designed to restore IgE levels, and in practice, IgE levels generally remain low or undetectable in patients on IRT. The clinical benefit comes from providing the IgG antibodies that do the heavy lifting against bacterial infections, particularly the respiratory tract infections that cause most of the morbidity in these patients.

In patients with X-linked agammaglobulinemia, IRT is a lifelong necessity. A case report illustrated this dramatically when a patient who interrupted his immunoglobulin infusions developed severe polymicrobial pneumonia with septicemia, which resolved within 48 hours after restarting intravenous immunoglobulin.¹⁴ That case underscores why adherence to the infusion schedule matters, especially in the most severe forms of antibody deficiency.

When Antibiotics Come First

Not every patient with low immunoglobulins is started on IRT immediately. For those with milder or “incomplete” antibody deficiency, clinicians sometimes try prophylactic antibiotics as a first step. The logic is straightforward: if a low dose of daily antibiotics prevents infections adequately, you can avoid the cost, inconvenience, and side effects of regular immunoglobulin infusions.

The evidence suggests this works for some patients but not others. In one study, patients who continued to have two or more infections per year despite prophylactic antibiotics saw a significant improvement when switched to IRT. Their average rate of respiratory tract infections dropped from about 2.6 per year on antibiotics alone to roughly 0.6 per year on immunoglobulin therapy.¹⁵ The practical takeaway: prophylactic antibiotics are a reasonable trial, but if infections keep breaking through, the conversation should shift to IRT.

Managing the Cancer Risk

Because low IgE is associated with certain malignancies, particularly blood cancers like CLL, some immunologists recommend heightened surveillance for patients with persistently undetectable IgE. There is no standardized screening protocol specific to IgE deficiency, but in practice this means staying attentive to unexplained lymph node swelling, abnormal blood counts, unexplained weight loss, and other classic warning signs of hematologic malignancy.

For CVID patients specifically, the combination of undetectable IgE and a trend toward lymphoma means that clinicians treating these patients tend to have a lower threshold for ordering imaging or biopsies when symptoms arise.⁵ The skin-test distinction mentioned earlier, where IgE-deficient patients with positive allergy skin tests show lower malignancy rates, could eventually become part of risk stratification, though it isn’t yet standard practice.

There is no therapy approved to boost IgE for the purpose of cancer prevention. The research connecting IgE to tumor surveillance is compelling enough to generate interest in therapeutic IgE antibodies designed to target tumors, but this work remains in early experimental stages. For now, the practical response to the IgE-cancer link is vigilance and appropriate screening, not a specific intervention aimed at raising IgE.

Treating the Autoimmune Complications

When autoimmune disease develops in the setting of low IgE, whether as part of CVID or in isolation, treatment follows the standard playbook for the specific autoimmune condition. Autoimmune cytopenias (where the immune system destroys blood cells) may be treated with corticosteroids, rituximab, or other immunosuppressants. The tricky part is that many immunosuppressive therapies can worsen the underlying antibody deficiency, so management requires balancing infection risk against autoimmune damage.

For CVID patients already on IRT, the immunoglobulin infusions themselves can sometimes help stabilize autoimmune cytopenias, though this benefit is inconsistent and additional immunosuppressive therapy is often still needed. The threefold higher risk of autoimmune disease in CVID patients with low IgE makes this a population where close immunology follow-up is particularly valuable.⁶

What About Selective IgE Deficiency With Normal Other Antibodies

This is the group that generates the most uncertainty. If your IgE is low or undetectable but your IgG, IgA, and IgM are all within normal range and you’re not getting sick more often than expected, what do you do? Honestly, the evidence base is thin here. The one patient in the immunodeficiency referral study who had low IgE with completely normal other immunoglobulins, including IgG subclasses, did not receive a diagnosis of antibody deficiency at all.³ In other words, isolated low IgE without broader immune dysfunction exists but appears to be genuinely rare when evaluated carefully.

For these patients, most immunologists recommend watchful waiting: periodic rechecking of immunoglobulin levels, attention to infection patterns, and age-appropriate cancer screening. There is no indication for IRT when the other immunoglobulins are normal and the patient is clinically well. The concern is that isolated IgE deficiency could be an early marker that evolves into a broader deficiency over time, though there are no long-term studies tracking this trajectory specifically.

Why There Is No IgE Replacement

You might wonder why IgE can’t simply be infused the way IgG is. The answer lies in IgE’s biology. IgE binds with extremely high affinity to receptors on mast cells and basophils throughout the body. Infusing IgE would arm those cells to degranulate, which is the process that causes allergic reactions, anaphylaxis, and potentially fatal hypotension. The therapeutic window between “enough IgE to restore immune surveillance” and “so much IgE that it triggers a systemic allergic response” is essentially nonexistent with current technology.

Research into anti-IgE therapies, which deliberately lower IgE to treat severe allergies and asthma, has paradoxically advanced our understanding of what happens when IgE goes away. Omalizumab, the most widely used anti-IgE biologic, binds free IgE and prevents it from attaching to mast cells. It is effective for allergic asthma and chronic hives but is obviously designed to reduce IgE, not increase it.¹⁶ The existence of patients on long-term omalizumab who maintain very low free IgE levels without developing the cancer or infection associations seen in primary IgE deficiency is an interesting puzzle, and it hints that the story is more nuanced than “low IgE equals bad.” In primary IgE deficiency, the low IgE is a marker of underlying B cell dysfunction that affects multiple arms of immunity; in drug-induced low IgE, the rest of the immune system remains intact.

The Gut Microbiome Connection

An emerging and still-early area of research involves the relationship between gut bacteria and IgE regulation. Studies in young children have found that the composition of gut bacteria correlates with IgE-related allergic responses. Specifically, reduced abundance of certain bacterial genera was linked to patterns of IgE production against airborne allergens like dust mites.¹⁷ This work is focused on allergy rather than IgE deficiency, but it raises the theoretical possibility that the microbial environment in the gut influences IgE class switching in B cells. Whether manipulating the microbiome could ever be used therapeutically to modulate IgE levels remains speculative. No probiotic or dietary intervention has been shown to raise IgE in deficient patients, and the complexity of the relationship between gut bacteria, mucosal immunity, and systemic antibody production means this is unlikely to translate into clinical practice soon. Still, it represents one of the few avenues where researchers are exploring what drives IgE production at a systems level, rather than simply cataloging what goes wrong when it’s absent.

1
Clinical Immunology. Characteristics of patients with low serum IgE levels and selective IgE deficiency: Data from an immunodeficiency referral center
2
PubMed Central. Immunoglobulin E, what is it good for?
3
PubMed Central. Low immunoglobulin E flags two distinct types of immune dysregulation
4
PubMed Central. Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID)
5
Annals of Allergy, Asthma & Immunology. Undetectable IgE association with noninfectious complications of common variable immune deficiency
6
PubMed. Relationship between autoimmune diseases and serum basal immunoglobulin E levels in patients with common variable immunodeficiency
7
PubMed Central. Clinical Characteristics of IgE Deficiency Among Patients with Primary Immunodeficiencies: Findings from the USIDNET Registry
8
Chest. Familial IgE Deficiency Associated with Sinopulmonary Disease
9
PubMed. Is There a Clinical Significance of Very Low Serum Immunoglobulin E Level?
10
Annals of Oncology. Elevated Total IgE and Risk of Cancer Demographics
11
PubMed Central. Low serum IgE is associated with an increased risk of chronic lymphocytic leukemia: a large retrospective cohort study
12
PubMed Central. The other side of the coin: IgE deficiency, a susceptibility factor for malignancy occurrence
13
PubMed Central. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders
14
PubMed Central. Severe Polymicrobial Pneumonia With Septicemia After Interruption of Immunoglobulin Replacement in X-Linked Agammaglobulinemia: A Case Report
15
PubMed Central. Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency
16
European Respiratory Review. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
17
PubMed Central. Gut microbial dysbiosis is associated with allergen-specific IgE responses in young children with airway allergies